teaser
Oral rivaroxaban tablets have been recommended by the National
Institute for Health and Clinical Excellence (NICE), the UK drug
recommendation body, as a new treatment option for prevention of
stroke and systemic embolism in patients with non-valvular atrial
fibrillation (AF) with one or more risk factors.
The NICE recommendation gives eligible patients cared for by the
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
UK health service with non-valvular AF in England and Wales
access to rivaroxaban – the first one tablet per day, oral stroke
prevention medicine since the introduction of warfarin in the 1950s.
NICE estimates that almost half (46%) of AF patients who should be
receiving warfarin are not currently taking it.
